I. Vergote

发表

The Role of Inhibins B and Antimüllerian Hormone for Diagnosis and Follow-up of Granulosa Cell Tumors

P. Neven, J. Billen, I. Geerts, 2009, International Journal of Gynecologic Cancer.

The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen.

D. Timmerman, P. Neven, D. Lambrechts, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα-targeting antibody-drug conjugate (ADC), with pembrolizumab in platinum-resistant epithelial ovarian cancer (EOC) patients

Cesar M. Castro, M. Birrer, A. Berkenblit, 2018, Gynecologic Oncology.

O001/#331 Empower-cervical 1/GOG-3016/ENGOT-CX9: results of phase 3 trial of cemiplimab vs investigator’s choice chemotherapy in recurrent/metastatic cervical carcinoma

Shin-ichiro Takahashi, A. Oaknin, D. Lorusso, 2021, Oral Abstracts.

Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinoma

C. Genestie, I. Vergote, I. Ray-Coquard, 2022, medRxiv.

LBA30 INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

A. Gadducci, J. Sehouli, N. Colombo, 2020 .

A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.

V. Gebski, R. Simes, J. Ledermann, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

V‐Y Bilateral gluteus maximus myocutaneous advancement flap in the reconstruction of large perineal defects after resection of pelvic malignancies

A. D'Hoore, F. Penninckx, R. Hierner, 2009, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

European Experts Consensus: BRCA/Homologous Recombination Deficiency Testing in First-Line Ovarian Cancer.

J. Brenton, I. Ray-Coquard, P. Pujol, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

gynaecological cancersA randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)

B. Monk, A. Tinker, A. Oza, 2016 .

LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)

I. Ray-Coquard, F. Selle, G. Scambia, 2022, Annals of Oncology.

FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC)

B. Monk, A. Oza, M. Birrer, 2019, Annals of Oncology.

723MO Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study

S. Pignata, M. Mirza, S. Banerjee, 2021, Annals of Oncology.

Weekly Paclitaxel (PAC), Pegylated Liposomal Doxorubicin (PLD) or Topotecan (TOP) ± Bevacizumab (BEV) in Platinum (PT)-Resistant Recurrent Ovarian Cancer (OC): Analysis by Chemotherapy (CT) Cohort in the GCIG Aurelia Randomised Phase III Trial

A. Reuss, P. Witteveen, F. Selle, 2012 .

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study)

Richard G. Moore, B. Monk, M. Mirza, 2019, Annals of Oncology.

Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe.

B. Monk, D. Cruickshank, M. Widschwendter, 2022, Gynecologic oncology.

The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.

V. Gebski, M. Friedlander, B. Ataseven, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety

B. Monk, M. Mirza, F. Backes, 2022, Annals of Oncology.

29PA NEGATIVE PROGESTERONE RECEPTOR IN LUMINAL HER-2 NEGATIVE BREAST CANCER BY AGE AT DIAGNOSIS: 10 YEARS FOLLOW-UP

P. Neven, M. Christiaens, H. Wildiers, 2014 .

Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial.

I. Ray-Coquard, N. Colombo, G. Scambia, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for post-progression PARP inhibitor therapy

J. Ledermann, G. Rustin, U. Matulonis, 2015 .

Association of PD-L1 expression and gene expression profiling with clinical response to pembrolizumab in patients with advanced recurrent ovarian cancer: Results from the phase II KEYNOTE-100 study.

D. Provencher, J. Ledermann, M. Birrer, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma

B. Monk, Shin-ichiro Takahashi, V. Samouëlian, 2021, Annals of Oncology.

Single agent, canfosfamide (C, TLK286) vs pegylated liposomal doxorubicin (D) or topotecan (T) in 3rd-line treatment of platinum (P) refractory or resistant ovarian cancer (OC): Phase 3 study results

D. Matei, S. Kaye, D. Spriggs, 2007 .

Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma.

P. van Damme, P. V. van Dam, I. Vergote, 1994, Journal of clinical pathology.

A randomized double-blind phase III trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) in combination versus PLD in participants with platinum-resistant ovarian cancer (PROCEED) (NCT01170650)

A. Oza, D. Provencher, P. Ghatage, 2015 .

532P Analyses of patient-reported outcomes (PROs) with mirvetuximab soravtansine (MIRV) versus standard chemotherapy in the randomized phase III FORWARD I study in ovarian cancer (GOG 3011)

A. Oza, M. Birrer, G. Scambia, 2022, Annals of Oncology.

Mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin and bevacizumab: Initial results from a phase Ib study in patients (pts) with ovarian cancer

Cesar M. Castro, D. Provencher, U. Matulonis, 2019, Annals of Oncology.

LBA30 Phase III ATALANTE/ov29 trial: Atezolizumab (Atz) versus placebo with platinum-based chemotherapy (Cx) plus bevacizumab (bev) in patients (pts) with platinum-sensitive relapse (PSR) of epithelial ovarian cancer (OC)

A. Floquet, D. Cibula, F. Heitz, 2022, Annals of Oncology.

A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy

B. Monk, A. Oza, M. Mirza, 2017 .

ENGOT-ov43/keylynk-001: A phase III, placebo- and active-controlled trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of advanced BRCA-nonmutated epithelial ovarian cancer

S. Lheureux, P. Zola, J. Sehouli, 2020, Gynecologic Oncology.

987TiPOReO/ENGOT Ov-38: A phase IIIb trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer

R. Glasspool, F. Marmé, B. Asselain, 2017 .

Reliability of core needle biopsy for determining ER and HER2 status in breast cancer.

M. J. van de Vijver, R. Tollenaar, J. Nortier, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen.

D. Timmerman, P. Neven, D. Lambrechts, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

B. Slomovitz, I. Vergote, I. Soumaoro, 2023, Annals of Oncology.

ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer

R. Wenham, S. Lheureux, P. Zola, 2019, Annals of Oncology.